Chemical tools to modulate ice formation/growth have great (bio)-technological value, with ice binding/antifreeze proteins being exciting targets for biomimetic materials. Here we introduce polymer nanomaterials that are potent inhibitors of ice recrystallisation using polymerisation-induced self-assembly (PISA), employing a poly(vinyl alcohol) graft macromolecular chain transfer agent (macro-CTA). Crucially, engineering the core-forming block with diacetone acrylamide enabled PISA to be conducted in saline, whereas poly(2-hydroxypropyl methacrylate) cores led to coagulation. The most active particles inhibited ice growth as low as 0.5 mg mL$^{-1}$, and were more active than the PVA stabiliser block alone, showing that the dense packing of this nanoparticle format enhanced activity. This provides a unique route towards colloids capable of modulating ice growth.

Ice formation and growth presents major challenges in the maintenance of infrastructure, adversely affects food texture and is a key consideration in the storage and transport of cells or vaccines. Extremophile organisms, which live in the coldest habitats make use of anti-freeze/ice-binding proteins (AFP/IBPs), ice-adhesion proteins as well as ice-nucleating proteins. It has emerged that it is possible to reproduce the desirable properties of these diverse proteins using materials science, including polymers (especially poly(vinyl alcohol), PVA) self-assembled small molecules, graphenics and minerals. One particularly desirable property is ice recrystallisation inhibition (IRI); the prevention of ice crystals from growing (distinct from nucleation). IRI-active materials have been found to improve post-thaw recovery of cryopreserved cells, proteins and bacteria. It is still not possible to rationally design new IRI, and in particular generating IRI-active polymer colloids/nanomaterials is challenging. Immobilisation of PVA onto gold particles by ‘grafting to’ retains, but does not enhance, activity as do coacervates. Similarly, assembly of Type III AFPs into dendrimers or on gold particles allows binding of multiple ice faces, but affords no overall increase in activity. This is surprising as AFP/IBPs typically show more activity as molecular weight or aggregation increases and theory predicts that the rate of ice nucleation requires large protein aggregates to function. Graphene oxide nanosheets also show strong particle size effects on ice formation. How large particles can bind and inhibit ice is not clear and if the design rules are related to that of protein/polymers is unknown. There is a clear opportunity to develop nanomaterials containing ice binding macromolecules with controlled presentation and architecture.

Polymerisation-induced self-assembly (PISA) has emerged as a powerful tool to generate multivalent polymeric nanomaterials of controlled morphology and size at high solid contents. The versatility of this method has allowed the synthesis of nano-objects for drug delivery, cell storage, permeable nanoreactors, and has been extensively reviewed. A challenge with many PISA formulations is the need to conduct PISA in biological media, which invariably contain salts. Armes and co-workers
Engineered stable nanoparticles by changing the steric stabilizer block to poly(sulfobetaines), to enhance solubility in the presence of salt. Cationic diblock spherical copolymer nanoparticles have also shown surprisingly strong aggregation resistance in electrolyte solutions. However, if PISA is to be used to design nanoparticles to interface and modulate the growth of ice, the corona-forming block is limited to polymers which can bind ice (e.g. PVA).

Taking into account the above, we here address the challenges of (i) conducting PISA in saline without restricting the corona-forming block, and (ii) introducing ice recrystallisation inhibition activity into polymer particles. This is achieved using diacetoxy acrylamide, rather than the common 2-hydroxypropyl methacrylate core-forming monomer, with a poly(vinyl alcohol) based macro-graft-RAFT agent. The resulting particles are potent IRI agents and present a unique approach to employ self-assembled colloidal dispersions for IRI.

Poly(vinyl alcohol) was selected as the corona-forming block, as it is the most active polymeric IRI agent known. Commercially available PVA (10 kDa/DP = 181) was selected which was grafted with 4-cyano-4-[ethylenesulfanylthiobenzyloxy]sulfanyl]pentanoic acid CTA (CEPA), by DCC coupling to afford a water soluble PVA-based graft macro-CTA. The macro-CTA was thoroughly dialysed to remove unfunctionalised RAFT agent. Due to overlapping signals, quantification of the grafting density by $^1$H NMR spectroscopy was not possible. Thermogravimetric analysis (TGA) showed that a ratio of four CEPA molecules per a hundred hydroxyl groups were present, meaning that approximately seven CTA groups were grafted per PVA chain (ESI†). SEC analysis of PVA181 graft macro-CTA revealed a small increase in molecular weight compared to PVA181 (ESI†).

The most widely used core-forming monomer for PISA, 2-hydroxypropyl methacrylate (HPMA), was used for thermally-initiated dispersion polymerisations at 60 °C (10% w/w) in water, and later in 0.01 M saline. NaCl is essential for IRI activity testing and lack of saline dispersibility would prevent assessment of activity. In water, monomer conversions above 95% (as confirmed by $^1$H NMR analysis) and stable PISA dispersions were obtained when targeting PHPMA degrees of polymerisation of 50–300. Dynamic light scattering revealed nanoparticles ranging in diameter from 200–400 nm as a function of PHPMA chain length. Dry-state TEM (Fig. 1C) revealed the formation of only spherical morphologies (see ESI† for all characterisation) and this was confirmed by cryo-TEM for PVA181-g7-PHPMA50 (Fig. 1D). We hypothesise that the graft nature of the macro-initiator, along with the high-molecular weight stabilising PVA chain, favours the formation of kinetically-trapped spherical morphologies, but further investigation is beyond the scope of this work. Attempts at dispersing these particles into NaCl (0.1 to 0.01 M) led to macroscopic precipitation. Alternatively, PISA was attempted directly in saline solutions, but no stable particles could be obtained. Therefore, this formulation, despite containing the desired PVA corona, could not be used for IRI activity measurements. The intolerance of many monomers used in PISA to saline solutions, specifically their inability to self-assemble and tendency to precipitate in such polar media, is a common challenge with PISA formulations and therefore saline-free buffers are often used.

It is not possible to change the PVA corona for another polymer as the PVA is the crucial ice-binding unit. To overcome the saline instability challenge, we therefore reasoned that tuning the core-forming block may enable saline-tolerant PISA. Diacetoxy acrylamide (DAAm) was investigated as an alternative. In contrast to HPMA, the DAAm reactions (using the same polymerisation conditions as above) led to stable nanoparticle dispersions in both water and in 0.01 M NaCl, with high conversions achieved (> 97%). It should be noted that we conducted the screening of PISA in saline, to ensure we selected stable particles, and to avoid problems due to osmotic pressures upon changing [NaCl], but we anticipate that aqueous synthesis followed by addition of saline could also be used. DLS and TEM analysis (Fig. 2) confirmed the formation of spheres in all cases, agreeing with our hypothesis (from the HPMA system) that the graft macro-RAFT agent constrains morphology evolution. We stress our aim here was to probe the IRI activity and not to explore the phase behaviour. Cryo-TEM imaging on particles also confirmed the formation of spheres (ESI†).

To evaluate the ice recrystallisation inhibition activity, the ‘splat’ assay was used. It is important to note that this assay requires saline to create channels between ice crystals, enabling recrystallisation to readily occur and hence avoid false positive results. For this reason the importance of our saline-stabilised PISA system cannot be understated. Polynucleated ice wafers were obtained from 10 µL droplets at –80 °C, then annealed at –8 °C for 30 minutes before being photographed and the average crystal size determined. This method separates nucleation from growth, and lower values of mean grain size (MGS) indicates higher activity. The IRI activity of particles from Fig. 2
are shown in Fig. 3. All the PISA formulations inhibited ice recrystallisation below 5 mg mL\(^{-1}\), and in some cases as low as 0.5 mg mL\(^{-1}\), placing them in the highly to very highly active range of antifreeze-protein mimetics.\(^{45}\) To enable comparison of multivalent effects (as the particles have different sizes) Fig. 3C shows the data in terms of total PVA concentration. At 0.5 mg mL\(^{-1}\) PVA\(_{181}\)-g-7-PDAAm\(_{300}\) showed IRI activity (MGS 40%) but as the core block length increased to PVA\(_{181}\)-g-7-PDAAm\(_{300}\) there was an increase with larger particles inhibiting growth at 0.1 mg mL\(^{-1}\) PVA. This activity, in terms of [PVA], was greater than the macro-CTA alone, implying a multivalent enhancement. Previous reports of PVA and antifreeze proteins grafted to particles or dendrimers\(^{24-27}\) gave no relative enhancement. We hypothesise that the dense packing of polymer chains in a PISA particle, compared to those obtained by ‘grafting to’ is crucial to enhance the IRI activity. It is important to note that the macro-CTA had lower IRI activity than pure PVA homopolymer. We used commercial PVA (~80% hydrolysis), which along with the grafted RAFT agent, breaks up the consecutive hydroxyl group sequence, which has been shown to be crucial for PVA IRI.\(^{13,52,53}\) The scaling behaviour of IRI’s in different salt solutions may also affect the magnitude of the results seen here.\(^{54}\) To further demonstrate the IRI activity, an alternative assay was conducted in 45 wt% sucrose (‘sucrose sandwich’).\(^{26,55}\) Fig. 3D shows nucleated ice crystals, which after 2 hours have grown significantly (recrystallised) in the absence of particles, Fig. 3E. Fig. 3F shows that solutions containing 1 mg mL\(^{-1}\) of PVA\(_{181}\)-g-7-PDAAm\(_{300}\) nanoparticles display complete inhibition of ice recrystallisation, demonstrating activity in a range of different formulations. Finally, ice morphology analysis was conducted. In these assays the temperature is varied to encourage crystal growth and to visualise any morphology changes. PVA is known to bind prismatic faces and hence produces faceting (Fig. 3G) compared to the solution alone (Fig. 3H), suggesting binding is occurring.\(^{15}\)
Conclusions

In summary, we present a new concept in the design of biomimetics for controlling ice growth, based upon polymer nanoparticles with densely grafted coronas. Polymerisation-induced self-assembly, PISA, was used as a scalable and tuneable tool to obtain polymer particles from a PVA-graft macroinitiator. By using DAA as the core-forming monomer, it was possible to conduct PISA directly in saline solution, compared to using HPMA which led to macroscopic coagulation. Using this system, spherical nanoparticles ranging from 200–400 nm were obtained and all were found to be capable of inhibiting ice recrystallisation. The larger particles were found to be more active than the smaller, and ice shaping analysis confirmed binding. These results show that it is possible to develop polymer particles capable of modulating ice growth processes, which may find application from biomedical to infrastructure challenges where ice is a problem. It also offers a practical solution to obtain saline-stable PISA assemblies.

Background data

The research data supporting this publication can be found at http://wrap.warwick.ac.uk.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

M. I. G. thanks the ERC (638661) and the Royal Society (191037). The UoW and Synthomer Ltd are thanked for providing a studentship to I. K. We acknowledge the University of Warwick Advanced Bioimaging Research Technology Platform supported by BBSRC ALERT14 award BB/M01228X/1 and Dr S. Bakker is for cryo-TEM. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 814236.

Notes and references

1 O. Parent and A. Ilinca, *Cold Reg. Sci. Technol.*, 2011, 65, 88–96.
2 A. Regand and H. D. Goff, *J. Dairy Sci.*, 2006, 89, 49–57.
3 B. L. Levine, J. Miskin, K. Wonnacott and C. Keir, *Mol. Ther. – Methods Clin. Dev.*, 2017, 4, 92–101.
4 C. Stubbs, T. L. Bailey, K. Murray and M. I. Gibson, *Biomacromolecules*, 2019, 21, 7–17.
5 G. J. Morris and E. Acton, *Cryobiology*, 2013, 66, 85–92.
6 A. Fowler and M. Toner, *Ann. N. Y. Acad. Sci.*, 2005, 1066, 119–135.
7 O. S. Kumru, S. B. Joshi, D. E. Smith, C. R. Middaugh, T. Prusik and D. B. Volkin, *Biologicals*, 2014, 42, 237–259.
8 P. L. Davies, *Trends Biochem. Sci.*, 2014, 39, 548–555.
9 R. N. Ben, *ChemBioChem*, 2001, 2, 161–166.
10 S. Guo, C. A. Stevens, T. D. R. Vance, L. L. C. Olijve, L. A. Graham, R. L. Campbell, S. R. Yazdi, C. Escobedo, M. Bar-Dolev, V. Yashunsky, I. Braslavsky, D. N. Langelaan, S. P. Smith, J. S. Allingham, I. K. Voets and P. L. Davies, *Sci. Adv.*, 2017, 3, e1701440.
11 K. E. Zachariassen and E. Kristiansen, *Cryobiology*, 2000, 41, 257–279.
12 C. I. Biggs, T. L. Bailey, Ben Graham, C. Stubbs, A. Fayer and M. I. Gibson, *Nat. Commun.*, 2017, 8, 1546.
13 T. Congdon, R. Notman and M. I. Gibson, *Biomacromolecules*, 2013, 14, 1578–1586.
14 B. Graham, A. E. R. Fayer, J. E. Houston, R. C. Evans and M. I. Gibson, *J. Am. Chem. Soc.*, 2018, 140, 5682–5685.
15 C. Budke and T. Koop, *ChemPhysChem*, 2006, 7, 2601–2606.
16 R. Drori, C. Li, C. Hu, P. Raiteri, A. Rohl, M. D. Ward and B. Kahr, *J. Am. Chem. Soc.*, 2016, 138, 13396–13401.
17 H. Geng, X. Liu, G. Shi, G. Bai, J. Ma, J. Chen, Z. Wu, Y. Song, H. Fang and J. Wang, *Angew. Chem., Int. Ed.*, 2017, 56, 997–1001.
18 T. F. Whale, M. Rosillo-Lopez, B. J. Murray and C. G. Salzmann, *J. Phys. Chem. Lett.*, 2015, 6, 3012–3016.
19 J. D. Atkinson, B. J. Murray, M. T. Woodhouse, T. F. Whale, K. J. Baustian, K. S. Carslaw, S. Dobbie, D. O. Sullivan and T. L. Malkin, *Nature*, 2013, 498, 355–358.
20 R. C. Deller, M. Vatish, D. A. Mitchell and M. I. Gibson, *Nat. Commun.*, 2014, 5, 3244.
21 R. M. F. Tomas, T. L. Bailey, M. Hasan and M. I. Gibson, *Biomacromolecules*, 2019, 20, 3864–3872.
22 D. E. Mitchell, A. E. R. Fayer, R. C. Deller, M. Hasan, J. Gutierrez-Marcos and M. I. Gibson, *Mater. Horiz.*, 2019, 6, 364–368.
23 M. Hasan, A. E. R. Fayer and M. I. Gibson, *Biomacromolecules*, 2018, 19, 3371–3376.
24 C. Stubbs, L. E. Wilkins, A. E. R. Fayer, M. Walker and M. I. Gibson, *Langmuir*, 2019, 35, 7347–7353.
25 C. C. M. Sproncken, R. Suris-Valls, H. E. Cingil, C. Detrembleur and I. K. Voets, *Macromol. Rapid Commun.*, 2018, 39, 1700814.
26 C. A. Stevens, R. Drori, S. Zalis, I. Braslavsky and P. L. Davies, *Bioconjugate Chem.*, 2015, 26, 1908–1915.
27 L. E. Wilkins, M. Hasan, A. E. R. Fayer, C. Biggs, M. Walker and M. I. Gibson, *Polyym. Chem.*, 2019, 10, 2986–2990.
28 Y. Wu, J. Banoub, S. V. Goddard, M. H. Kao and G. L. Fletcher, *Comp. Biochem. Physiol., Part B: Biochem. Mol. Biol.*, 2001, 128, 265–273.
29 S. Mahatabuddin, Y. Hanada, Y. Nishimiya, A. Miura, H. Kondo, P. L. Davies and S. Tsuda, *Sci. Rep.*, 2017, 7, 42501.
30 Y. Qiu, A. Hudait and V. Molinero, *J. Am. Chem. Soc.*, 2019, 141, 7439–7452.
31 G. Bai, D. Gao, Z. Liu, X. Zhou and J. Wang, *Nature*, 2019, 576, 437–441.
32 N. J. Warren and S. P. Armes, *J. Am. Chem. Soc.*, 2014, 136, 10174–10185.
33 W.-J. Zhang, C.-Y. Hong and C.-Y. Pan, *Macromol. Rapid Commun.*, 2019, 40, 1800279.
34 D. B. Wright, M. A. Touve, L. Adamiak and N. C. Gianneschi, *ACS Macro Lett.*, 2017, 6, 925–929.
35 D. E. Mitchell, J. R. Lovett, S. P. Armes and M. I. Gibson, *Angew. Chem., Int. Ed.*, 2016, 55, 2801–2804.
36 I. Canton, N. J. Warren, A. Chahal, K. Amps, A. Wood, R. Weightman, E. Wang, H. Moore and S. P. Armes, *ACS Cent. Sci.*, 2016, 2, 65–74.
37 L. D. Blackman, S. Varlas, M. C. Arno, A. Fayter, M. I. Gibson and R. K. O’Reilly, *ACS Macro Lett.*, 2017, 6, 1263–1267.
38 L. D. Blackman, S. Varlas, M. C. Arno, Z. H. Houston, N. L. Fletcher, K. J. Thurecht, M. Hasan, M. I. Gibson and R. K. O’Reilly, *ACS Cent. Sci.*, 2018, 4, 718–723.
39 S. L. Canning, G. N. Smith and S. P. Armes, *Macromolecules*, 2016, 49, 1985–2001.
40 N. J. W. Penfold, J. Yeow, C. Boyer and S. P. Armes, *ACS Macro Lett.*, 2019, 8, 1029–1054.
41 F. D’Agosto, J. Rieger and M. Lansalot, *Angew. Chem., Int. Ed.*, 2020, 59, 2–27.
42 S. Varlas, J. C. Foster and R. K. O’Reilly, *Chem. Commun.*, 2019, 55, 9066–9071.
43 K. E. B. Doncom, N. J. Warren and S. P. Armes, *Polym. Chem.*, 2015, 6, 7264–7273.
44 S. J. Byard, A. Blanazs, J. F. Miller and S. P. Armes, *Langmuir*, 2019, 35, 14348–14357.
45 C. I. Biggs, C. Stubbs, B. Graham, A. E. R. Fayer, M. Hasan and M. I. Gibson, *Macromol. Biosci.*, 2019, 19, 1900082.
46 C. A. Knight, J. Hallett and A. L. DeVries, *Cryobiology*, 1988, 25, 55–60.
47 S. J. Byard, M. Williams, B. E. McKenzie, A. Blanazs and S. P. Armes, *Macromolecules*, 2017, 50, 1482–1493.
48 D. Li, M. Huo, L. Liu, M. Zeng, X. Chen, X. Wang and J. Yuan, *Macromol. Rapid Commun.*, 2019, 40, 1900202.
49 A. Blanazs, A. J. Ryan and S. P. Armes, *Macromolecules*, 2012, 45, 5099–5107.
50 N. Guerrouani, B. Couturaud, A. Mas, F. Schü and J.-J. Robin, *Eur. Polym. J.*, 2013, 49, 1621–1633.
51 L. I. Atanase, J. Desbrieres and G. Riess, *Prog. Polym. Sci.*, 2017, 73, 32–60.
52 P. M. Naullage, L. Lupi and V. Molinero, *J. Phys. Chem. C.*, 2017, 121, 26949–26957.
53 P. M. Naullage and V. Molinero, *J. Am. Chem. Soc.*, 2020, 142(9), 4356–4366.
54 R. Suris-Valls and I. K. Voets, *Biomolecules*, 2019, 9, 347.
55 C. Budke, A. Dreyer, J. Jaeger, K. Gimpel, T. Berkemeier, A. S. Bonin, L. Nagel, C. Plattner, A. L. Devries, N. Sewald and T. Koop, *Cryst. Growth Des.*, 2014, 14, 4285–4294.